Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Several Emerging Therapies are Poised to Provide Improvements in Safety and Tolerability and/or Delivery, According to Findings from Decision Resources Group
BURLINGTON, Mass., Feb. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that greater reduction in pain intensity and a greater patient responder rate (measured by the percentage of patients reporting at least 30 percent or at least 50 percent reduction in pain intensity from baseline) are the top two areas of unmet need in painful diabetic neuropathy (PDN) treatment. Additionally, because PDN is a chronic pain condition that requires prolonged treatment, maintenance of pain relief over the long-term is critical but often difficult to achieve with current treatments. Novel pain therapies able to address these needs would be well-positioned for both favorable formulary inclusion and physician uptake.
Other key findings from the DecisionBase report entitled Painful Diabetic Neuropathy: In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain?:
Comments from Decision Resources Group Analyst Andrea Buurma:
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.